Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

IMPORTANCE: Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1 receptor agonist, with other classes of glucose-lowering therapy. OBJECTIVE: To compare efficacy and assess long-term adverse event profiles of once-daily oral semaglutide vs sitagliptin, 100 mg added on to metf...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA
Glavni autori: Rosenstock, Julio, Allison, Dale, Birkenfeld, Andreas L., Blicher, Thalia Marie, Deenadayalan, Srikanth, Jacobsen, Jacob Bonde, Serusclat, Pierre, Violante, Rafael, Watada, Hirotaka, Davies, Melanie
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2019
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6484814/
https://ncbi.nlm.nih.gov/pubmed/30903796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.2942
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items